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Background: A proline-to-serine substitution at position-56 (P56S) of vesicle-associated membrane
protein-associated protein B (VAPB) causes a form of dominantly inherited motor neuron disease (MND), including
typical and atypical amyotrophic lateral sclerosis (ALS) and a mild late-onset spinal muscular atrophy (SMA). VAPB is
an integral endoplasmic reticulum (ER) protein and has been implicated in various cellular processes, including ER
stress, the unfolded protein response (UPR) and Ca2+ homeostasis. However, it is unclear how the P56S mutation
leads to neurodegeneration and muscle atrophy in patients. The formation of abnormal VAPB-positive inclusions by
mutant VAPB suggests a possible toxic gain of function as an underlying mechanism. Furthermore, the amount of
VAPB protein is reported to be reduced in sporadic ALS patients and mutant SOD1G93A mice, leading to the
hypothesis that wild type VAPB plays a role in the pathogenesis of ALS without VAPB mutations.
Results: To investigate the pathogenic mechanism in vivo, we generated human wild type (wtVAPB) and mutant
VAPB (muVAPB) transgenic mice that expressed the transgenes broadly in the CNS. We observed robust
VAPB-positive aggregates in the spinal cord of muVAPB transgenic mice. However, we failed to find an impairment
of motor function and motor neuron degeneration. We also did not detect any change in the endogenous VAPB
level or evidence for induction of the unfolded protein response (UPR) and coaggregation of VAPA with muVAPB.
Furthermore, we crossed these VAPB transgenic mice with mice that express mutant SOD1G93A and develop
motor neuron degeneration. Overexpression of neither wtVAPB nor muVAPB modulated the protein aggregation
and disease progression in the SOD1G93A mice.
Conclusion: Overexpression of VAPBP56S mutant to approximately two-fold of the endogenous VAPB in mouse
spinal cord produced abundant VAPB aggregates but was not sufficient to cause motor dysfunction or motor
neuron degeneration. Furthermore, overexpression of either muVAPB or wtVAPB does not modulate the course of
ALS in SOD1G93A mice. These results suggest that changes in wild type VAPB do not play a significant role in ALS
cases that are not caused by VAPB mutations. Furthermore, these results suggest that muVAPB aggregates are
innocuous and do not cause motor neuron degeneration by a gain-of-toxicity, and therefore, a loss of function may
be the underlying mechanism.
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Motor neuron diseases (MND) are a group of diverse
neurological disorders with motor neuron involvement
that include amyotrophic lateral sclerosis (ALS), pri-
mary lateral sclerosis, spastic paraplegias, progressive
muscular atrophy, spinal muscular atrophy (SMA), and
spinobulbar muscular atrophy [1]. ALS, also referred
to as Lou Gehrig’s disease, is the most common adult-
onset motor neuron disease caused by degeneration of
upper and lower motor neurons, accompanied by pro-
gressive weakness, muscle wasting and fasciculations,
spasticity, dysarthria, dysphagia, and respiratory com-
promise. While 90% of ALS cases are sporadic without
known genetic mutations, 10% of the cases are familial,
which are caused by more than a dozen genetic muta-
tions [2]. Among them, a proline-to-serine substitution
at position-56 (P56S) of vesicle-associated membrane
protein-associated protein B (VAPB) in the highly con-
served major sperm protein (MSP) domain causes some
dominantly inherited forms of MND (ALS8), which
show typical and atypical ALS symptoms or a mild late-
onset spinal muscular atrophy (SMA) [3,4]. A second
missense mutation in VAPB causing an amino acid
change from threonine to isoleucine at codon 46 (T46I),
also in the MSP domain, has been proposed as a causa-
tive factor in a single case of familial ALS (fALS) [5].
VAPB belongs to a well conserved VAP family of pro-
teins. VAPB is an integral membrane protein of the
endoplasmic reticulum (ER) with an amino terminal
MSP domain, a central coiled-coil motif and a carboxy-
terminal transmembrane domain anchored in ER mem-
brane [6-12]. VAPB has roles in neurotransmitter
release [13], ER to Golgi transport [14,15], bouton for-
mation at the neuromuscular junction [16], Ca2+
homeostasis [6,17] and signaling via Eph receptors [18]
and Robo and Lar-like receptors [19]. VAPB has also
been implicated in other cellular processes, including
endoplasmic reticulum (ER) stress and the unfolded
protein response (UPR), in which VAPBP56S is func-
tionally abnormal in these processes [5,10,18,20-22].
While some studies have shown that VAPBP56S can
enhance ER stress and the UPR [18,21], others have
associated VAPBP56S with an inhibitory effect on the
UPR [5,10,20,22]. It is unclear what functional and
structural changes induced by ALS/MND-related muta-
tions in VAPB lead to neurodegeneration and muscle at-
rophy in patients.
Similar to many neurodegenerative disorders, the
two known VAPB mutants can form aggregates
[4,5,7,12,21,23,24], which also sequester wild type
VAPB and VAPA [12,25]. It is possible that VAPB
mutations cause ALS/MND by a dominant-negative
effect and/or a gain of toxicity from its protein
aggregates and recruitment of wild type VAPB andVAPA proteins into these aggregates, especially in
motor neurons. To test this hypothesis, we generated
both wild type VAPB (wtVAPB) and VAPB P56S
(muVAPB) transgenic mice with broad expression in
the CNS and peripheral tissues and observed robust
formation of VAPB positive aggregates in the spinal
cord of the muVAPB, but not the wtVAPB transgenic
mice. However, we detected neither motor dysfunc-
tion nor motor neuron degeneration. These results
do not support the gain-of-toxicity mechanism for
mutant VAPB-induced ALS.
It has been suggested that VAPB deficiency may play a
broad role in the pathogenesis of familial ALS (fALS)
and sporadic ALS (sALS) because decreased levels of
VAPB have been reported in patients with sALS and the
SOD1G93A mouse model [12,26]. On the other hand,
VAPBP56S may cause pathogenesis of the disease by a
gain of toxic function [27]. Therefore, we crossed both
muVAPB and wtVAPB transgenic mice with SOD1G93A
mice to determine whether the muVAPB and wtVAPB
modulate the course of the disease caused by the SOD1
mutation. If there was a gain of toxic function or a dom-
inant negative effect due to muVAPB overexpression, we
expected to observe an adverse effect of muVAPB on
SOD1G93A mice, such as accelerated disease onset and
progression. Conversely, if the decreased level of VAPB
played a significant role in the pathogenesis of ALS, we
would observe a slowing in the disease progression in
the SOD1G93A and wtVAPB double transgenic mice.
However, neither muVAPB nor wtVAPB overexpression
affected the disease onset or progression caused by mu-
tant SOD1, suggesting that mutant VAPB does not have
a gain of toxicity and VAPB levels do not modulate
the disease course of ALS cases without the VAPB
mutations.
Results
Overexpression of human mutant or wild type VAPB in
the transgenic mice
To investigate the role of VAPB in ALS, we created both
wtVAPB and muVAPB transgenic mice. To differentiate
the human VAPB versus the mouse endogenous VAPB,
we added a 3xFLAG-tag at the N-terminus of human
VAPB. We used a strong and ubiquitously active CAG
promoter to drive the expression of the transgenes
(Figure 1A). We designed the vectors with the loxP
sequences flanking the VAPB transgene, so that if neuro-
degeneration occurred, we would cross these transgenic
mice with various neuron- or glia-specific Cre driver
lines to determine the cellular origin of the mutant
toxicity, as had been shown in other studies [28,29].
However, we did not carry out these crosses because, as
will be detailed below, our transgenic mice did not de-
velop neurodegeneration. Nevertheless, we note that this
Figure 1 Overexpression of wtVAPB or muVAPB in the spinal cord and brain of the transgenic mice. (A) Schematic diagram showing the
transgene construct. This construct has a CAG promoter, which drives the expression of human VAPB gene that is tagged by 3XFLAG
(marked as 3XFL) at its N-terminal. The 3X poly A sequences (3XpA) after the VAPB gene terminate the transcription. Therefore, the RFP gene is
not expressed. The two triangles represent the loxP sequence that flank the VAPB transgene. (B) VAPB levels from two lines of muVAPB and one
line of wtVAPB transgenic mice were determined by Western blot. For the detection of VAPB in the spinal cords, 100 μg protein was loaded in
each lane. The proteins were resolved by a 12% SDS-PAGE and detected as described in the materials and methods. For the detection of VAPB in
the brains, 30 μg protein was loaded in each lane. Due to its 3XFLAG tag, the molecular weight of the transgenic VAPB (as indicated by *) is
slightly more than the endogenous mouse VAPB protein.
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the results from such crosses would be difficult to inter-
pret even if neurodegeneration should occur in these
mice [30].
The construct was verified by expression of the trans-
gene after transient transfection into HEK293 cells and
subsequent Western blot for the FLAG-tagged VAPB
protein (data not shown). After pronuclear injection, a
total of 14 wtVAPB and 23 muVAPB transgenic founder
lines were generated and then screened for the expression
of the transgene in brains and spinal cords by Western
blot with anti-FLAG or anti-VAPB antibody. One wtVAPB
line (wtVAPB) and two muVAPB lines (muVAPB35 and
muVAPB60) that showed the highest levels of expression
in the spinal cords were further studied. In wtVAPB trans-
genic mice, the transgenic hVAPB protein level was 2–3
times higher than the mouse endogenous VAPB level in
both the spinal cord and forebrain, while the protein levels
of muVAPB in the lines muVAPB35 and muVAPB60 were
slightly higher than the endogenous mouse VAPB level in
the spinal cord and lower than the endogenous level in
the forebrain (Figure 1B). To achieve a higher expression
level of muVAPB, the two muVAPB lines were crossed to
obtain double transgenic mice (muVAPB35/60), which
expressed the muVAPB at a level approximately the same
as the wtVAPB mice in the spinal cord and approximately
equal to the endogenous VAPB level in the forebrain
(Figure 1B). Notably, the expression of transgenic VAPB
did not alter the expression level of the endogenous VAPB
as compared with the level in the non-transgenic (NTG)
control. In addition to the CNS, the transgene was alsoexpressed in peripheral tissues, including the skeletal
muscle, heart, spleen, liver and lung (data not shown).
Overexpression of muVAPB, but not wtVAPB, led to VAPB
aggregation
We examined the expression pattern of the transgene in
different cell types in spinal cord sections by immuno-
fluorescence staining. An increased staining intensity was
observed in the wtVAPB transgenic lines (Figure 2A,B)
compared with NTG mice (Figure 2A,B) but no aggre-
gates were detected. In contrast, muVAPB transgenic mice
showed aggregates throughout the whole spinal cord
(Figure 2A,B). In the ventral horn area, where motor
neurons are located, the aggregates were found in the
cytoplasm of the motor neurons in the muVAPB trans-
genic mice (Figure 2A,B). The aggregates were detected in
both mutant lines at similar levels and were increased in
number and size in the double transgenic mice gene-rated
from crossing the two mutant lines (Figure 2A). Thus,
only muVAPB proteins, but not wtVAPB proteins, form
aggregates in the transgenic mice.
muVAPB overexpression did not cause motor dysfunction
or affect motor neuron survival
To determine whether there was any phenotypic conse-
quence of muVAPB expression, we closely monitored
any overt phenotypic changes in the muVAPB transgenic
mice and did not find any difference from the NTG
mice up to >600 days of age. There was no significant
difference in body weight between the muVAPB mice
and NTG mice as they aged (Figure 3A). To determine
Figure 2 (See legend on next page.)
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Figure 2 Overexpression of muVAPB, but not wtVAPB, causes aggregation. (A) Lumbar spinal cord sections from different transgenic lines
(NTG, wtVAPB, muVAPB35, and muVAPB35/60) were stained with VAPB antibody. VAPB-positive inclusions were found throughout the whole
spinal cord in the muVAPB mice but not in the wtVAPB mice. The inserts show high magnification of the boxed areas in the large image.
Aggregates are indicated by arrows. Scale bars: 30 μm. (B) Motor neurons in muVAPB mice, but not in wtVAPB mice, show VAPB aggregates. The
neurons were marked by staining for neurofilaments high molecular weight subunit (NF-H). The VAPB aggregates are indicated by arrows in the
figure. Scale bars: 10 μm.
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several motor behavioral analyses. We did not detect a
significant difference in rotarod performance or grip
strength tests between the muVAPB and NTG mice
(Figure 3B-D).
To determine whether there was motor neuron degen-
eration as a consequence of VAPB aggregation, we
examined spinal cords and ventral roots. We detected
no evidence for degeneration of motor neurons or their
axons in either wtVAPB or muVAPB transgenic mice
(Figure 4A,B). Quantification of the total number of ven-
tral root axons from 18-month old muVAPB35/60 mice
showed no significant difference from the NTG controls
(Figure 4C). Additionally, we detected no evidence for
astrogliosis or microgliosis (Figure 4D) and there was no
change in muscle morphology indicative of denervationFigure 3 Age-associated changes in body weight and motor function
weight between female muVAPB and NTG mice up to 600 days old. For ea
(B) No significant difference among muVAPB35/60 (n = 4), muVAPB35 (n =
12 months. (C, D) Grip strength tests of the forelimbs (C) and combined fo
mice at different ages. The number of mice tested from each genotype at
averages with standard deviation.atrophy (Figure 4E). Notably, no evidence of neurode-
generation was found even in the muVAPB35/60 double
transgenic mice, where muVAPB expression and aggre-
gation were further elevated (Figures 1, 2 and 4). These
observations demonstrate that a 2-fold overexpression of
either wtVAPB or muVAPB does not cause motor dys-
function and motor neuron degeneration in mice.
VAPB aggregation did not lead to typical ALS pathology
Formation of TAR-DNA binding protein (TARDBP, also
known as TDP43)-positive intracellular inclusions in the
central nervous system (CNS) is the most common
pathology in the patients with ALS and frontotemporal
lobar degeneration (FTD), even in the absence of TDP-
43 mutations [31-33]. The formation of intracellular
TDP-43-containing inclusions is accompanied by ain VAPB transgenic mice. (A) No significant difference in the body
ch time point, 6 to 21 mice from each genotype were analyzed.
11) and NTG (n = 11) mice in rotarod test at the age of 10 to
relimbs and hindlimbs (D) in female NTG and muVAPB35 transgenic
each time point is in the range of 4 to 22. All values are displayed as
Figure 4 No significant pathological change in 18-month old VAPB transgenic mice. Spinal cord sections (A) of the ventral horn area and
L3 ventral root nerve sections (B) from different genotypes are shown. All plastic sections were cut at 1 μm thickness and stained with toluidine
blue. Scale bars: 20 μm. (C) Numbers of total axons of the ventral roots (L3 and L4) from 18-month old mice were counted. No significant
difference in the numbers of axons was found between muVAPB35 (n = 5) and NTG (n = 4) mice. All values are shown as averages with standard
deviation. (D) No evidence of microgliosis and astrogliosis was detected in the spinal cord of muVAPB35/60 mice, as compared with NTG mice.
The sections from the lumbar spinal cords were stained with Iba1 and GFAP antibodies (green fluorescence) to show microglia and astrocytes,
respectively. The nuclei were shown by DAPI stain. Scale bars: 20 μm. (E) No pathological change in the muscles from transgenic mice.
Gastrocnemius muscle sections from NTG, wtVAPB, and mutVAPB35/60 were stained with H&E. Scale bars: 50 μm.
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mation is available regarding the involvement of TDP-43
pathology in patients with VAPB mutations, although a
subtle change in TDP-43 distribution and ubiquination
have been reported in a VAPBP56S transgenic mouse
line [24]. To investigate the correlation between VAPB
mutation and TDP-43 pathology, we performed TDP-43
staining in our muVAPB35/60 double transgenic mice,
which contain most robust VAPB aggregates. As shown
in Figure 5A, we detected no obvious change in TDP-43
staining pattern in the spinal cord motor neurons of 18-
month old muVAPB35/60 and wtVAPB transgenic mice.
Protein aggregates in neurodegenerative diseases are
marked by ubiquitin and p62, which implies an ongoing
clearance process of these aggregates by the cellular pro-
tein quality control system [35]. To examine whether
there is a clearance process against the VAPB aggregates,
we stained motor neurons for ubiquitin and p62. We
detected no labeling of ubiquitin in the majority of VAPB
aggregates and only occasional weak labeling in some
aggregates (Figure 5B, arrows). We also detected no p62
labeling of the VAPB aggregates (data not shown). These
results suggest that VAPB aggregates differ from the
pathogenic aggregates such as those derived from mutant
SOD1 (Figure 5B) that trigger the response from the cellu-
lar protein quality control system.muVAPB did not cause structural change in ER or
coaggregate with VAPA
VAPB protein is normally located in the ER membrane
[6]. Aggregation of mutant VAPB has been shown to be
associated with ER stress [5,10,18,20-22]. In order to de-
termine whether VAPB aggregates co-localize with ER
proteins and have an adverse effect on ER integrity, we
used PDI as a marker for ER structure and ER stress. We
did not detect any change in the PDI staining pattern and
PDI did not coaggregate with VAPB aggregates (Figure 6),
suggesting the ER structure remains unaltered. We further
compared the ER structure between spinal cord motor
neurons of the muVAPB35/60 mice and NTG controls by
electron microscopy (Figure 7A) and did not find any evi-
dence of ER structural defect in the double mutant mice.
Additionally, we examined mitochondrial morphology
and could not find any notable differences between the
double mutant mice and the age-matched NTG controls
(Figure 7A). To determine whether there are functional
changes, we investigated whether the UPR was activated.
We quantified the expression levels of Chop (Ddit3) and
BiP (Hspa5) in the muVAPB35 mice relative to those in
the NTG mice by RT-PCR (Figure 7B). We did not detect
any significant changes in the expression levels. Our
results suggest that overexpression of mutant VAPB does
not change the ER structure or induce the UPR.It has been shown that wild type VAPB and VAPA can
be sequestered in the aggregates with muVAPB [12]. Be-
cause we did not have means to differentiate the trans-
genic VAPB and the endogenous wild type mouse VAPB,
we chose to examine VAPA in the spinal cords from
muVAPB35/60 double transgenic mice with VAPA anti-
body. However, we did not observe any VAPA aggre-
gates, suggesting that VAPA was not sequestered in
muVAPB aggregates (Figure 8).
muVAPB aggregation did not affect disease progression
in SOD1G93A mice
A previous study suggested that VAPB plays a role in the
pathogenesis of ALS caused by Cu/Zn superoxide
dismutase-1 (SOD1) mutations [12]. The study showed
that the levels of VAPB were decreased in motor neurons
of the mutant SOD1 mice, implicating the involvement of
VAPB deficiency in the ALS disease progression. In order
to investigate the possible effect of overexpressed VAPB
on the disease progression of SOD1G93A transgenic mice,
we crossed both wtVAPB and muVAPB transgenic mice
with SOD1G93A ALS mice. We expected to observe an
adverse effect of muVAPB overexpression on the disease
course of SOD1G93A mice if there is a gain of toxic func-
tion or a dominant negative effect on the endogenous
VAPB function. Additionally, if VAPB deficiency plays a
significant role in the pathogenesis of ALS, we would ob-
serve a delayed onset and/or extended survival in the
double transgenic SOD1G93A/wtVAPB mice. However,
our results revealed that neither muVAPB nor wtVAPB
overexpression altered the disease onset as determined by
the peak body weight (Figure 9A) or the progression as
determined by the lifespan (Figure 9B) in SOD1G93A
mice. These results demonstrate that VAPB does not
modulate the course of ALS disease.
In some model systems, one mutant protein misfolding
and aggregation can augment the misfolding and aggrega-
tion of another mutant protein [36]. To determine
whether this type of interaction exist between VAPBP56S
and SOD1G93A, we performed a sedimentation assay to
compare the amount of aggregated protein in the single
and double transgenic mice generated from the crosses
between VAPB and SOD1G93A transgenic mice. The re-
sult showed that most of the endogenous mouse VAPB
was soluble with only a small amount detected in the in-
soluble fraction (Figure 10A, lane 1). This pattern was not
altered by the overexpression of muVAPB (lane 2),
wtVAPB (lane 7), SOD1G93A (lane 5), both muVAPB and
SOD1G93A (lanes 3 and 4) or both wtVAPB and
SOD1G93A (lane 6). Noticeably, the fraction of insoluble
muVAPB (lanes 2–4) was increased compared with the
wtVAPB (lanes 6, 7). The increase of the insoluble
muVAPB was particularly obvious in the muVAPB35/60
double transgenic mice (lane 4). But increased muVAPB
Figure 5 No significant TDP-43 pathology and ubiquitin-positivity in the muVAPB transgenic mice. (A) No TDP-43 aggregation or change
in its cellular distribution in the spinal cords of VAPB transgenic mice was detected. Frozen sections from lumbar spinal cords from NTG, wtVAPB
and muVAPB35/60 mice at 18-month old were stained with VAPB and TDP-43 antibodies. Scale bars: 10 μm. (B) Ubiquitin staining was absent or
weak in motor neurons with muVAPB aggregates. Frozen sections from cervical spinal cords from NTG and muVAPB35/60 at 18-month old were
stained with ubiquitin and VAPB antibodies. The sections from mutant SOD1 mice at their end stage were stained in parallel as positive controls.
Scale bars: 6 μm. The VAPB aggregates are indicated by arrows in the figure. The nuclei are shown by DAPI stain.
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Figure 6 muVAPB did not affect ER integrity. Frozen sections from the lumbar spinal cords of NTG, wtVAPB and muVAPB35/60 mice at
18-month old were stained with VAPB and PDI antibodies. VAPB aggregates are indicated by arrows. Scale bars: 10 μm.
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dogenous VAPB (compare lanes 2–4 with lane 1) or the
insoluble amount of mutant SOD1 (compare lanes 3 and
4 with lane 5). To determine whether muVAPB and
SOD1G93A coaggregate, we carried out double immuno-
fluorescence staining. We found that mutant VAPB and
SOD1 formed independent aggregates in cells (Figure 10B).
These results demonstrate that overexpression of muVAPB
or wtVAPB does not impact on the insoluble fraction of the
endogenous wild type VAPB and mutant SOD1, thus sug-
gesting that there is no significant coaggregation of the
endogenous wild type VAPB with the mutant VAPB and
that the aggregation of muVAPB does not interact with the
aggregation of the mutant SOD1.
Discussion
Compared to the previous VAPB transgenic study [24],
our results showed stronger and broader muVAPB
aggregates, especially in motor neurons. Our muVAPB
transgenic model with wide-spread aggregation forma-
tion could provide a useful tool to test the possible
gain-of-toxic function due to protein misfolding and ag-
gregation. Yet despite a systematic investigation with
multiple analytic assays, we failed to find evidence for
neurodegeneration or dysfunction in the transgenic
mice. Although a two-fold overexpression of muVAPB may
not have reached the toxic threshold, and therefore, maynot be sufficient to trigger motor neuron degeneration, the
failure of muVAPB to enhance mutant SOD1 toxicity
diminishes the possibility of a harmful role of mutant VAPB
in motor neuron degeneration. A further support for the
innocuous nature of muVAPB is the absence of any patho-
logical hallmarks, including structural changes of ER and
mitochondria, evidence of UPR, reactive astrogliosis and
microgliosis, redistribution of TDP-43, and activation of
cellular protein quality control systems.
Our results contrast with some previous literature
reports. Overexpression of muVAPB has been reported
to alter ER morphology and modulate UPR in vitro
[5,7,12,18]. Our data do not support these roles in vivo.
In an analysis of a VAPBP56S transgenic mouse line,
Tudor and colleagues reported a redistribution of TDP-
43 from nucleus to the cytoplasm and the presence of
ubiquitin- and p62-labeled structures in motor neurons
[24]. We have not confirmed their observation in our
muVAPB mice. The reason of this discrepancy is not
clear. A simple explanation might be that the mutant
VAPB was expressed at a higher level in their mice than
in the mice used in this study. Consistent in both studies,
however, is the observation that overexpression of
muVAPB does not cause motor neuron degeneration phe-
notypes. Therefore, the results from both of these studies
do not support the possibility that a gain of toxicity in mu-
tant VAPB causes motor neuron degeneration.
Figure 7 muVAPB did not cause structural change for ER and mitochondria or induce UPR response. (A) ER and mitochondrial
morphology in the motor neurons from the lumbar spinal cords of muVAPB35/60 mice at 18-month old were not different from the NTG
controls. (Abbreviations: Mit-mitochodria, Lf-lipofuscin, Nuc-nucleus, ER-endoplasmic reticulum.) Scale bars: 5 μm. (B) Relative ratios of Chop and
BiP mRNA from the spinal cords of muVAPB35 mice at the age of 14 months as determined by RT-PCR and compared to the age-matched NTG
mice. All values are represented by mean±SD. No significant difference was detected.
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mic protein aggregates, including mutant or the wild
type proteins of SOD1 [37,38], TDP-43 [39-41], and
FUS/TLS [42]. However, it is not clear what roles these
aggregates play in the pathogenesis of the disease.Indeed, it is controversial whether the aggregation is detri-
mental to cell survival. For example, neurodegeneration is
still induced by ALS-related TDP-43 mutations in the
absence of cytoplasmic TDP-43 aggregates, suggesting
TDP-43 aggregation may not be required for pathogenesis
Figure 8 muVAPB did not cause coaggregation of VAPA. Sections from the lumbar spinal cords from NTG and muVAPB35/60 mice at
18-month old were stained for VAPA. NF-H was stained as a marker for neurons. The cell nuclei were shown by DAPI stain. Scale bars: 20 μm.
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tect neurons by reducing the levels of toxic soluble forms
of mutants, as has been shown in mutant huntingtin [45].
It is possible that the neurodegeneration is not due to the
presence of cytoplasmic aggregates, but by altered func-
tion of the mutant protein [46,47]. In human MND caused
by VAPB mutations, the cellular mechanism leading to
motor neuron degeneration and muscle atrophy is not
known. Although robust VAPB aggregates were formed in
the muVAPB transgenic mice, especially in the motor neu-
rons, our results have revealed that motor neurons could
tolerate the VAPB aggregates without degeneration, sug-
gesting that VAPB protein aggregation may not play a sig-
nificant role in the pathogenesis.
Whether VAPB aggregation has a role in human
patients with VAPB mutations is not clear. In fact, itFigure 9 Overexpression of neither wtVAPB nor muVAPB significantly
mice. (A) The effect of overexpression of muVAPB on the weight changes
SOD1G93A (n = 12), SOD1G93A and muVAPB35 double transgenic (n = 10),
analyzed. (B) The survival of the male mice from SOD1G93A (n = 27), SOD1
muVAPB35/60 triple transgenic (n = 27), and SOD1G93A and wtVAPB doubremains to be established that VAPB cytoplasmic aggre-
gates exist in ALS8 patients. Motor neurons derived
from iPS cells from ALS8 patients with the known
VAPB-P56S mutation have decreased levels of VAPB
without VAPB aggregation [48], which is consistent with
the loss-of-function hypothesis. In this study, we
detected no decrease in the endogenous VAPB level, nor
did we attain evidence for involvement of VAPA or en-
dogenous VAPB in the VAPB aggregates. This result
does not support the possibility that the mutant VAPB
exerts a dominant negative effect on the normal allele by
coaggregation. Furthermore, in the presence of wide-
spread VAPB aggregates, especially in the CNS, no
neurodegeneration or motor dysfunction was observed,
which does not support the toxic gain-of-function hy-
pothesis. Therefore, future studies to determine whetherimpacted on the disease progression and survival of SOD1G93A
in SOD1G93A mice. The weight data of the male mice from
SOD1G93A and muVAPB35/60 triple transgenic mice (n = 10) were
G93A and muVAPB35 double transgenic (n = 27), SOD1G93A and
le transgenic mice (n = 6) were analyzed.
Figure 10 VAPBP56S and SOD1G93A aggregates did not interact with each other. (A). Mouse spinal cord lysates were centrifuged to
separate the soluble and insoluble fractions. One hundred μg of both fractions were loaded on the gel and blotted for VAPB, FLAG, SOD1 and
tubulin. The asterisks mark the 3XFLAG tagged VAPB, which is above the endogenous mouse VAPB. (B). muVAPB and SOD1G93A aggregate
independent of each other in the same motor neuron in the spinal cord of the muVAPB35 and SOD1G93A double transgenic mice. The sections
from the lumbar spinal cord were stained with VAPB and hSOD1 antibodies. The nuclei were shown by DAPI stain. Scale bar: 5 μm.
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ism for the mutant VAPB is of critical importance.
Previous studies have shown that VAPB levels were
reduced in sporadic ALS patients and SOD1G93A mice
[12,26], suggesting that VAPB dysfunction may contributeto ALS in general. We tested this possibility by overexpres-
sion of either the mutant or the wild type VAPB in
SOD1G93A mice. Our results demonstrate that neither the
mutant nor the wild type VAPB had any impact on the
course of the disease in the SOD1G93A mice. These results
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not have VAPB mutations.
Since protein aggregation is common in many neuro-
degenerative diseases, it has been proposed that
the protein aggregation weakens the capacity of cellular
proteostasis, thus enhancing the cell vulnerability to
secondary assault(s) from another misfolding-prone
protein [35]. Our muVAPB/SOD1G93A double trans-
genic mice enabled us to test whether mutant SOD1
aggregation enhances mutant VAPB aggregation and
vice versa in a mammalian system. Our data showed
that VAPBP56S and SOD1G93A aggregate independ-
ently and do not enhance each other’s aggregation.
Therefore, the synergistic protein misfolding and aggre-
gation may not occur in all experimental systems. In
addition, since VAPB aggregation did not cause motor
neuron degeneration, and in particular, did not enhance
mutant SOD1 toxicity, some protein aggregation may
be innocuous and all protein aggregation does not inev-
itably lead to cellular toxicity.
Conclusion
Overexpression of mutant but not wild type VAPB leads
to robust VAPB-positive aggregates. However, motor
neurons are capable of tolerating these aggregates with-
out degeneration, thus suggesting that mutant VAPB
does not cause ALS through toxicity associated with
its aggregation. Furthermore, overexpression of either
muVAPB or wtVAPB does not modulate protein aggre-
gation and the course of the ALS in SOD1G93A mice,
suggesting that VAPB does not play a significant role in
ALS patients that do not have VAPB mutations. Import-
antly, mutant VAPB and mutant SOD1 aggregate inde-
pendently and do not augment each other’s aggregation,
thus suggesting that aggregation-prone proteins do not
inevitably lead to deterioration of cellular proteostasis.
Overall, our results do not support a gain of toxic function
or a dominant negative effect as the underlying mechan-
ism for muVAPB-induced neurodegeneration. Therefore,
future experiments need to test the loss-of-function
hypothesis.
Methods
Transgene constructs
Human VAPB (hVAPB) cDNA clone in the vector
pCMV6-XL5 was purchased from OriGene. Proline at
position-56 was changed to Serine by converting C to T
at the 166th position using a site-directed mutagenesis
kit (Qbiogene) with the PCR primers 50-CCACGTAGG
TACTGTGTGAGGTCCAACAGCGGAATCATCGAT-30
and 50-ATCGATGATTCCGCTGTTGGACCTCACACA
GTACCTACGTGG-30. The mutation was confirmed
by sequencing both strands. Wild type hVAPB
(hVAPBWT) and hVAPBP56S fragments were amplifiedby PCR with the primers flanked by EcoRI and KpnI
sites and cloned in the plasmid vector p3XFLAG-CMV-
7 (Sigma) with the same restriction enzyme sites to
obtain two intermediate vectors (all enzymes were
obtained from New England Biolabs unless otherwise
indicated). The 3XFLAG tag was added to differentiate
the transgene from the mouse endogenous VAPB gene.
We used a previously described pCAG-EGFP/RFP-
miRNAint plasmid [49] to construct the transgenic
constructs (Figure 1A). The EGFP encoding fragment
in the plasmid was cut out with Cla1 digestion, blunted
by Klenow, and then cut by Sph1. The large fragment
of the vector was gel-purified for subsequent cloning.
The 3xFLAG-hVAPBWT and 3xFLAG-hVAPBP56S
fragments were amplified by PCR from the intermedi-
ate vectors, blunted with T4 polymerase, and digested
with SphI. The transgenic vectors pCAG-wtVAPB/RFP
and pCAG-muVAPB/RFP were constructed by ligation
of the large vector fragment and the 3xFLAG hVAPB
WT or 3xFLAG hVAPB P56S fragment, respectively.
All cloning procedures were verified by DNA sequencing.
Generation and propagation of transgenic mice
The expression vectors, pCAG-wtVAPB/RFP and pCAG-
muVAPB/RFP, were linearized by digestion with the re-
striction enzymes Ssp1 and Pci1 and subsequently purified
as previously described [30]. The linearized DNA con-
structs were injected into C57BL/6 × SJL F2 hybrid mouse
embryos by the UMassTransgenic Animal Modeling
Core. Mouse tails of 2 mm in length were cut for PCR-
based genotyping. Tail DNA samples were prepared by
DirectPCR Lysis Reagent (Viagen Biotech) according to
the provided instructions. Positive transgenic mice were
identified by a 185 bp fragment within the open reading
frame of the human VAPB gene produced by PCR using
the primer pair 50- AGTCTCTGAGTTCTTCTTTGG -30
and 50-CTTCCCAGTTGGGGCTA-30. The PCR program
was set as 4 minutes at 95°C, followed by 40 cycles of
95°C for 30 seconds, 51°C for 20 seconds, and 72°C for
30 seconds. The transgenic mice were maintained as
heterozygotes by crossing with FVB/NJ mice. SOD1G93A
(B6.Cg-Tg(SOD1*G93A)1Gur/J) transgenic mice [50] were
obtained from Jackson Laboratory and crossed with FVB/
NJ for ten or more generations. All mice were maintained
at the University of Massachusetts Medical School animal
facility according to the guidelines set forth by the Institu-
tional Animal Care and Use Committee (IACUC) and all
animal procedures were approved by the IACUC.
Histological analyses
Mice under deep anesthesia were transcardially perfused
with cold PBS followed by cold fixation buffer contain-
ing 4% paraformaldehyde in PBS. Tissues were dissected
out and immersed in the same fixative overnight at 4°C.
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2–3 days at 4°C, and then frozen in OCT media (Sakura,
Torrance, CA). Frozen sections at 10 μm thickness were
cut by a cryostat and air-dried on slides at room
temperature for 30 minutes. For immunofluorescence
staining, slides were incubated in the blocking solution
(5% normal goat serum and 0.2% Triton X-100 in PBS,
pH7.4) for 30 min at RT, rinsed three times in PBS, and
incubated with primary antibodies in the blocking solu-
tion overnight at 4°C. The slides were subsequently
washed with PBS three times and incubated with sec-
ondary antibodies in the blocking solution for 2 hr at RT
in dark. After washing, the slides were mounted with
Vectashield mounting medium containing 40,60-diami-
dino-2-phenylindole (DAPI, Vector Laboratories). Images
were taken with a Nikon Eclipse Ti microscope equipped
with NIS elements software and further processed by the
three-dimensional deconvolution program AutoQuant X2
(Media Cybernetics). The following antibodies were used:
VAPB (ProteinTech Group), Iba1 (BioCare Medical),
GFAP (Cell Signaling), TDP-43 (ProteinTech Group
and Encor Biotechnology), NF-H (Covance), Ubiquitin
(Millipore), PDI (Stressgen), and SOD1 (Biodesign). The
secondary goat anti-rabbit, goat anti-mouse or donkey
anti-sheep IgG (Invitrogen) conjugated by Alexa Fluor-
488 or Alexa Fluor-555 were used.
For muscle histology, samples were obtained from
fixed mice, embedded in paraffin blocks, sectioned and
stained with Hematoxylin & Eosin (H&E).
For nerve and spinal cord plastic sections, the cervical
and lumbar spinal cords and the L3 and L4 nerve roots
were dissected from mice fixed with 4% paraformalde-
hyde and further fixed in 4% paraformaldehyde plus
2.5% glutaraldehyde in 0.1 M phosphate buffer, pH7.6
for 3 to 5 days. Plastic sections at 1 μm were processed
and stained with toluidine blue. For electron microscopy,
thin sections of ventral horn were cut from the Epon tis-
sue blocks, stained with uranyl acetate and lead citrate,
and proceeded for examination under a Philips CM-10
transmission electron microscope.
In all experiments, NTG mice were processed in paral-
lel as negative controls. For ubiquitin and p62 staining,
the end stage mutant SOD1 mice were used as positive
controls.
Western blotting
Mouse tissues were homogenized at a ratio of 100 mg/ml
in homogenization solution (50 mM Tris HCl pH7.4, 1%
SDS, 0.05% Triton X-100, 1 mM EGTA and protease in-
hibitor mixture) for 1 minute by using the Fast Prep-24
(MP Biomedicals). The resultant tissue lysates were heated
at 95°C for 5 min followed by vortexing at low speed. After
centrifugation at 13000 rpm for 5 min, the supernatants
were stored at −80°C.Protein samples (50 μg each) were resolved on a 10%
SDS-polyacrylamide gel (Bio-Rad) for subsequent West-
ern blotting. The membrane was probed with anti-FLAG
(Stratagene,1:2000), anti-VAPB (ProteinTech Group,
1:1000), or anti-SOD1 antibody (Biodesign,1:10,000).
The protein bands were visualized using the SuperSignal
West Pico kit (Pierce). After detecting VAPB, the blot
was stripped and reprobed with anti-tubulin primary
antibody (Sigma, 1:10,000).
Rotarod test
Before the actual test, mice were trained on an auto-
mated 4-lane rotarod unit (Columbus Instruments) for
three days. The rotarod was set to an accelerating mode
from 13 to 72 rpm over a period of 5 minutes. The ani-
mals were tested for three consecutive days and three
times each day with a rest of 15 minutes between each
trial. The length of time that each animal was able to
stay on the rod was recorded. The best performance of
each animal on each day was used to calculate the aver-
age performance for the three days.
Grip strength test
A device with a force gauge (Chatillon, DFM2) con-
nected with a stainless steel grid was used for the test.
For forelimb grip strength measurement, the mouse was
gently lowered over the top of the grid so that only its
front paws can grip the grid. The mouse was pulled
away from the grid until it released the grip. For com-
bined forelimb and hind limb measurement, the mouse
was lowered over the top of the grid so that both its
front and hind paws can grip the grid. The mouse was
pulled away horizontally and steadily until it released its
grip. Each animal was measured three times and the
peak grip strength value of the animal was recorded as
its performance.
RT-PCR
The RT-PCR was done as previously described [30].
Briefly, total RNA was extracted from mouse tissues by
Trizol reagent (Invitrogen) followed by treatment with
DNase I (Promega) and cDNA synthesis by using Super-
Script III kit (Invitrogen). Quantitative PCR was per-
formed by using Sybr Green mix (Qiagen). The primer
pair 50-TCCTGTCCTCAGATGAAATTGG-30 and 50-
CCACTCTGTTTCCGTTTCCTA-30 were designed for
the mouse Chop gene (Ddit3) with a product size of
241 bp. The primer pair 50-TTCAATGGCAAGGAGC
CATC-30 and 50-TGATTATCGGAAGCCGTGGA-30 were
designed for the mouse BiP gene (Hspa5) with a product
size of 239 bp. Mouse reference gene glyceraldehyde-3-
phosphate dehydrogenase (Gapdh) was amplified with the
primer pair 50-CTGGAGAAACCTGCCAAGTA-30 and
50-TGTTGCTGTAGCCGTATTCA-30, which produce a
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3 minutes at 95°C, followed by 40 cycles of 15 seconds at
95°C, 30 seconds at 58°C, and 20 seconds at 72°C. ΔCt
values were calculated by subtracting the Ct values of
Gapdh from those of Chop or BiP. ΔΔCt values were
derived by subtracting the ΔCt values of the wild type from
those of the transgenic mice, which were then used to cal-
culate the levels of the mRNA in the transgenic mice rela-
tive to those in the controls. All the RT-PCR reactions were
done by using the CFX96 Real-Time System (Bio-Rad).
Sedimentation assay
Mice of different genotypes were generated from crossing
wtVAPB transgenic or muVAPB35/60 double transgenic
mice with SOD1G93A mice and were analyzed at the age
of 95 to 100 days. Mouse tissues were mixed at a ratio of
1:10 with pre-chilled lysis buffer containing 50 mM Tris–
HCl (pH 7.4), 1% Triton X-100, 1 mM EDTA, 150 mM
KCl, and 1% multiple protease inhibitors (Sigma).
Homogenization was done using the handheld polytron
for 20 sec on ice. The lysates were centrifuged at 12,000 g
for 5 min at 4°C. The supernatants were collected as the
soluble fraction. The pellets were homogenized in the
same buffer and centrifuged. The supernatants were dis-
carded. The pellets were homogenized for 10 sec in the
buffer containing 50 mM Tris HCl pH 7.4, 1% SDS, 0.05%
Triton X-100, 1 mM EGTA and protease inhibitor mix-
ture. One fifth of the original lysis buffer volume was used.
Following the homogenization, the homogenate was vor-
texed vigorously for 10 sec. The resulting lysates were
incubated at 95°C for 10 min and vortexed vigorously
again for 10 sec. The samples were left at room temp to
cool and then centrifuged at 13000 rpm for 5 min at room
temperature. These supernatants were collected as the in-
soluble fraction. All the soluble and insoluble parts were
used for Western blotting as stated above.
Statistical analysis
Student’s t-test was used for statistical analysis.
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